“Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis With Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 1, Jan. 2021, p. s18, https://doi.org/10.25251/skin.5.supp.18.